Screening Compounds

ZereneX promotes more than 300 target-focussed libraries as well as small molecule screening libraries for high-throughput screening and fragment-based research. Our focused compound libraries comprise collections of compounds with in silico predicted affinity to a target protein or predicted biological activity.

•  Disease-Based Libraries - Alzheimer's disease, diabetes, cancer

•  Phenotypic Screening Library

•  RNA Binding

•  Epigenetic Targets

•  Protein-Protein Interaction

•  Peptidomimetics

•  Glycomimetics

•  Protein Kinases

•  Proteases

•  GPCRs

•  Nuclear Receptors

•  Ion Channels

•  Fragment Libraries

•  General Activities

For further details please contact us at enquiries@zerenex-molecular.com

Top of page

Industry News

Entrants so far have come from Shire, Bayer, AbbVie, Eisai Europe, Novartis, GSK, MSD, Lundbeck, HFA Healthcare Products, Sandoz and...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us